PaTHway Phase 3 Trial Analysis
Treatment-Emergent Adverse Events (≥5 patients in total)
Preferred Term
Patients with at least one TEAE, n (%)
TEAEs
Injection site reaction
Headache
Hypocalcaemia
Fatigue
Paraesthesia
Muscle spasms
Nausea
Arthralgia
Diarrhoea
Hypercalcaemia
Constipation
Insomnia
24 Data on file, Ascendis Pharma 2022.
Pathway
TransCon PTH
(N = 61)
50 (82.0)
Placebo
(N = 21)
21 (100.0)
19 (31.1)
13 (21.3)
0
2 (9.5)
6 (9.8)
9 (42.9)
9 (14.8)
5 (23.8)
11 (18.0)
3 (14.3)
7 (11.5)
3 (14.3)
7 (11.5)
2 (9.5)
6 (9.8)
2 (9.5)
6 (9.8)
1 (4.8)
6 (9.8)
0
4 (6.6)
1 (4.8)
4 (6.6)
1 (4.8)
TransCon PTH is an investigational product candidate.
For investor communication only.
Not for use in product promotion. Not for further distribution.
ascendis
pharma
TRIALView entire presentation